Abstract: Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with typically aggressive behavior. The genetic signature is the chromosomal translocation t(11;14)(q13;q32) resulting in overexpression of cyclin D1. Asymptomatic newly diagnosed MCL patients with low tumor burden can be closely observed, deferring therapy to the time of disease progression. Although MCL classically responds to upfront chemotherapy, it remains incurable with standard approaches. For patients in need of frontline therapy, the initial decision is whether to proceed with an intensive treatment strategy or a non-intensive treatment strategy. In general, given the unfavorable risk-benefit profile, older MCL patients should be spared intensive strategies, while younger and fit patients can be considered for intensive strategies. The bendamustine and rituximab (BR) regimen is becoming an increasingly popular treatment option among the elderly population, with improved progression-free survival (PFS) and acceptable side-effect profile. Although rituximab maintenance after R-CHOP improves survival outcomes in elderly patients, no clinical trial to date has shown statistical significance to support the use of rituximab maintenance after BR induction in older patients. In young and fit patients with MCL, an intensive strategy to maximize the length of first remission has emerged as a worldwide standard of care. With current high-dose cytarabine-containing immunochemotherapy regimens followed by autologous stem cell transplantation, the median PFS has exceeded 7 years. In the relapsed or refractory (R/R) setting, reduced intensity conditioning allogeneic hematopoietic stem cell transplantation may offer the highest likelihood of long-term survival in young R/R MCL patients, at the cost of increased risk of non-relapse mortality and chronic graft versus host disease. Novel agents targeting activated pathways in MCL cells, such as bortezomib, lenalidamide, ibrutinib and temsirolimus are now available for the management of R/R disease.
Introduction
Mantle cell lymphoma (MCL) comprises approximately 7% of all non-Hodgkin lymphoma (NHL) cases. [1] [2] [3] The median age at diagnosis is 68, with a 3:1 male predilection. [1] [2] [3] MCL has typically been considered an aggressive and incurable B-cell lymphoma. The 2016 WHO Classification of lymphoid malignancies has recognized two separate types of MCL:
• classical MCL, usually composed of IGHVunmutated B-cells, and SOX11 expression; 4 the classical variant of MCL has a tendency to involve lymph nodes and extranodal sites;
• leukemic non-nodal MCL, generally composed of IGHV-mutated genes without SOX11 expression. The leukemic nonnodal variant typically involves the bone marrow, peripheral blood and spleen, and mostly has an indolent presentation. 4 Multiple studies in the past decade have elucidated the wide range of biological events contributing to MCL pathogenesis. The recognition of the translocation t(11;14)(q13;q32) resulting in cyclin D1 (CCND1) overexpression was an evolutionary event in improving our understanding of the clinical and biological diversity of this tumor. 5, 6 In addition to CCND1 overexpression causing deregulation of the cell cycle at the G1/S phase transition, other mechanisms such as DNA damage response alterations (CHK1 and CHK2), 6 and activation of cell survival pathways, such as overexpression of antiapoptotic genes (BCL2) 7 are other known pathways described in MCL pathogenesis. 8 In terms of clinical manifestations, one-third of MCL patients present with high levels of lactate dehydrogenase (LDH), 25% of patients present with B symptoms, and less than 5% of patients have CNS involvement at some point throughout their course of disease. [9] [10] [11] In this article we review the clinical and biologic risk factors that are currently applied in risk stratification of MCL, discuss the optimal initial therapeutic options in young/fit and elderly treatment-naïve patients, outline viable treatment choices in the relapsed or refractory (R/R) setting and summarize the current literature supporting novel agents and strategies.
Identification of clinical and biologic risk factors in MCL
In 2008, Hoster and colleagues reviewed data from 455 advanced-stage MCL patients treated within three clinical trials, and developed the MCL international prognostic index (MIPI) of overall survival (OS). The MIPI score was created based on four independent prognostic factors including age, performance status, LDH and leukocyte count. According to the MIPI score, patients were categorized into low risk [44% of patients, MIPI score <5.7, median OS not reached (NR)], intermediate risk (35%, 5.7 ⩽ MIPI score ⩽ 6.1, median OS 51 months) and high-risk groups (21%, score ⩾ 6.2, median OS 29 months). Hoster and colleagues also explored the prognostic relevance of cell proliferation index (Ki-67), and demonstrated that it is an important biologic marker with added prognostic value. 12 Additional work from Sarkozy and colleagues studied the prognostic role of genetic abnormalities in addition to t(11;14)(q13;q32). A high MIPI score, a complex karyotype -defined as ⩾3 additional abnormalities, and blastoid morphology were shown to be independently associated with worse survival outcomes. A score based on these factors allowed for the separation of 'indolent' patients [median treatment-free survival (TFS) 107 months] from other patients (median TFS 1 month). 13 In a concerted effort to combine clinical and biologic prognostic factors, the European MCL Network used the cohort from the European MCL Younger and MCL Elderly trials to evaluate the additional prognostic impact of cytology and growth pattern to improve risk stratification with the Ki-67 index and MIPI. In the combined cohort, blastoid cytology was associated with inferior OS independent of MIPI, but not independent of the Ki-67 index. Growth pattern did not prove to be an independent prognostic factor. These results revealed a superior prognostic value for the Ki-67 index compared to cytology and growth pattern in MCL. This study also confirmed the prognostic value of the previously validated 30% cutoff for the Ki-67 index. 12 The 16 Another group investigating intensive strategies for older MCL patients reported the outcomes for 38 patients with MCL aged ⩾60 years who received R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) (n = 19) or R-HyperCVAD (n = 19) with or without autologous stem cell transplantation (ASCT). After a median length of follow up of 2.7 years, the median progression-free survival (PFS) of R-CHOP + ASCT was 3.2 years versus 4 years in R-HyperCVAD alone. Both strategies provided longer PFS than that of R-CHOP alone, 1.6 years. Compared with R-CHOP alone, R-HyperCVAD induction resulted in an increased incidence of toxicity, including treatment discontinuation and transfusion requirement, although rates of adverse events were similar for R-HyperCVAD alone and R-CHOP + ASCT. These results showed R-CHOP alone is a less adequate strategy for fit older patients with MCL.
Intensifying therapy with R-HyperCVAD induction or R-CHOP followed by ASCT consolidation is associated with prolonged PFS and similar rates of toxicity. 17 While these two groups demonstrated that intensive strategies are superior to historical outcomes realized with R-CHOP, newer approaches appear to produce outcomes similar to intensive strategies and with substantially less toxicity.
For example, Robak and colleagues investigated whether replacing vincristine in R-CHOP by bortezomib in frontline therapy could improve outcomes in patients with newly diagnosed MCL who were transplant ineligible. In this phase III trial, 487 patients were randomly assigned to receive 6-8 cycles of R-CHOP (n = 244) or VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone) (n = 243). At a median follow up of 40 months, the median PFS was 14.4 months in the R-CHOP group versus 24.7 months in the VR-CAP group. This study showed superior outcomes for VR-CAP compared to R-CHOP at the cost of increased hematologic toxicity. 18 Bendamustine-rituximab (BR) has been shown to be an effective induction strategy in older MCL patients. Rummel and colleagues conducted a prospective, multicenter, randomized trial to compare BR with R-CHOP as first-line treatment for patients with indolent and mantle cell lymphomas. Of a total of 549 patients, 94 (17%) carried a diagnosis of MCL. Of these 94 patients, 46 were assigned to the BR arm and the remaining 48 were assigned to the R-CHOP arm. The median age in both groups was 70. At a median follow up of 45 months, the median PFS was 35.4 months in the BR group versus 22.1 months in the R-CHOP group. Increased PFS, along with an acceptable side-effect profile, has made the BR regimen a popular first-line treatment option in treatment-naïve older MCL patients. 19 To further improve the BR outcomes in the elderly patient population, an Italian group conducted a phase II study, combining cytarabine with rituximab and bendamustine (R-BAC) in treatmentnaïve or R/R MCL patients older than 65 years of age. The maximum tolerated dose (MTD) for cytarabine in stage one of this phase II study was determined to be 800 mg/m 2 . The ORR and 2-year PFS rate were 100% and 95% for previously untreated and 80% and 70% for R/R patients respectively. 20 To reduce the hematologic toxicity associated with the R-BAC800 regimen, the same group later performed another phase II study to investigate the efficacy and side-effect profile of the R-BAC500 regimen (cytarabine 500 mg/m 2 ). The results in 57 patients enrolled in this phase II study were reported at the 2016 American Society of Hematology (ASH) annual meeting, and indicated a significant improvement in hematologic toxicity without compromising survival outcomes. 21 Another innovative phase II study explored the combination of rituximab and lenalidomide (R 2 regimen) with induction and maintenance phases. The median age of 38 enrolled patients was 65 years. At the median follow up of 30 months, the ORR was reported to be 92%, with a CR rate of 64%. Median PFS was not reached. The 2-year PFS was estimated to be 85%, and the 2-year OS 97%. 22 Although this combination biologic therapy provided a promising early signal, longer follow up and confirmation in a larger cohort is needed before this strategy can be endorsed.
In summary, based on the Stil trial, 19 the BR regimen appears to be superior in terms of significant improvement in PFS in conjunction with a more tolerable side-effect profile. VR-CAP is a reasonable treatment strategy if bendamustine is not a viable option. Ongoing trials (SHINE and E1411) are testing novel agents (Shine -ibrutinib; E1411 -bortezomib) onto a BR backbone to determine if outcomes can be further improved in the elderly patient population with MCL. Table 1 offers a summary.
Maintenance strategies for elderly MCL patients
Given the high response rates, but relatively brief remission duration to induction therapy, the notion of maintenance therapy has intuitive appeal in MCL. Multiple studies have explored the role of maintenance strategies upon the conclusion of induction therapy to improve the outcomes of older patients with MCL.
The European MCL Network conducted a study to compare rituximab, fludarabine and cyclophosphamide (R-FC) to R-CHOP. Patients who achieved a response underwent a second randomization to maintenance therapy with rituximab or interferon alpha, each continued until disease progression. This study enrolled 560 patients with a median age of 70 years. Mainly due to excess toxicity, the OS was significantly shorter with R-FC compared to R-CHOP, 4-year OS 47% versus 62% (p = 0.005), respectively. In total, 316 patients who responded to induction chemotherapy were randomly assigned to either rituximab maintenance (n = 155) or interferon alpha (n = 161). At a median follow up of 36 months, the median duration of remission (mDOR) was 23 months in the interferon alpha arm, while it was not reached in the rituximab maintenance arm. At a median follow up of 42 months, the median OS was 64 months in the interferon alpha group, whereas it was not reached in the rituximab maintenance group. These results indicated rituximab maintenance following R-CHOP induction regimen can improve response duration and potentially OS. 23 Based upon the promising results noted in the Stil trial, BR is growing as an increasingly popular induction strategy in the elderly MCL patients. To further improve the survival outcomes of BR induction, Rummel and colleagues investigated the role of rituximab maintenance versus observation after first-line treatment with BR in patients with previously untreated MCL. Following BR induction, responders to BR regimen were then randomized to either rituximab maintenance (375 mg/m 2 every 2 months for a total of 2 years) or observation only. Of 120 patients, 59 (49%) were randomized to rituximab maintenance and 61 (51%) to observation. Median patient age was 70 years. At a median follow up of 54.2 months, the median PFS was 54.7 in the observation arm, but not yet reached in the rituximab maintenance arm. The difference in PFS between the two study groups did not reach statistical significance. 24 In summary, the European MCL Network showed rituximab maintenance after R-CHOP improves survival outcomes. However, R-CHOP is a suboptimal induction strategy. BR, with good efficacy and acceptable toxicity profile, appears to be a better platform for older MCL patients. To this date, clinical trials have failed to demonstrate statistical evidence supporting the benefit of rituximab maintenance after BR in the treatment of older patients with MCL. More study is needed to conclusively answer this question.
Management of young and fit MCL patients
In general, intensive strategies produce more durable remissions in MCL. The impact of intensive treatment on OS is less clear. For the purposes of this review, intensive treatment encompasses any strategy that includes ASCT as consolidation or intensive chemotherapy such as conventional R-HyperCVAD with alternating R-MTX/Ara-C. If patients are young (age <65), fit and appropriate candidates for intensive therapy, this is a very reasonable approach.
Induction strategies for young and fit MCL patients
As mentioned in the elderly section, the University of Texas M. D. Anderson Cancer Center group experience with hyper-CVAD alternating with R-MTX/Ara-C included 97 patients with de novo MCL. Among patients aged ⩽65 years (n = 65), the 5-year FFS was 60%, with a median FFS of 5.5 years. 16 The Cancer and Leukemia Group B (CALGB) 59909 trial explored the feasibility, safety and effectiveness of an aggressive immunochemotherapy regimen containing rituximab combined with methotrexate and augmented CHOP (RM-CHOP) followed by ASCT for patients up to age 69 years with a new diagnosis of MCL. Seventy-eight patients were enrolled, and the median age of patients was ASCT, autologous stem cell transplantation; BR, bendamustine, rituximab; CI, confidence interval; mFFS, median failure-free survival; IQR, interquartile range; N/A, not available; NR, not reached; OS, overall survival; PFS, progressionfree survival; R 2 , rituximab, lenalidomide; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-HyperCVAD, rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; R-MTX/Ara-C, high-dose methotrexate/cytarabine; VR-CAP, bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone.
57 years. At a median follow up of 4.7 years, the median event-free survival (EFS) was 4.4 years. The 2-year PFS was 76% (95% CI; 64-85%), and the 2-year OS was 87% (95% CI; 77-93%). 25 Subsequent efforts focused on exploring the role of high-dose cytarabine (HiDAC) as part of the induction regimen prior to ASCT in young, newly diagnosed MCL patients. In a study by Delarue and colleagues, 60 patients with a median age of 57 years were enrolled, and treated with three cycles of R-CHOP (rituximab only received in the third cycle) followed by three cycles of R-DHAP (rituximab plus dexamethasone, HiDAC and cisplatin). Responding patients were considered for an ASCT. At a median follow up of 67 months, median EFS was 83.9 months (range 71.5-NR), median PFS was 84 months and median OS was not reached. Five-year OS rate was 75%. 26 Following the aforementioned phase II trial, 26 in an elaborate effort the European MCL Network aimed to further investigate whether the introduction of HiDAC to immunochemotherapy prior to ASCT results in better outcomes. In a randomized phase III trial, patients 65 years of age or younger were assigned to either six cycles of R-CHOP followed by ASCT (n = 234) versus six cycles of alternating R-CHOP and R-DHAP followed by ASCT (cytarabine group, n = 232). After a median follow up of 6.1 years, the median PFS was 4.3 years (95% CI; 3.8-5) in the R-CHOP + ASCT group, compared to 9.1 years (95% CI; 6.5-NR) in the cytarabine group. Given the outstanding results, this study suggested immunochemotherapy containing HiDAC followed by ASCT to be considered as the standard of care in younger patients with MCL. 27 Other groups have also investigated the role of further intensification of induction regimen in MCL to improve survival outcomes. In 2008, at that time based on a median follow-up time of 4 years, the Nordic MCL group published the early results of the second Nordic MCL trial of frontline intensive induction immunochemotherapy consisting of dose-intensified R-CHOP (maxi-CHOP), alternating with R + HiDAC for a total of six cycles followed by ASCT. The early results indicated the 6-year OS, EFS, and PFS to be 70%, 56%, and 66%, respectively, and no relapses reported after 5 years in 160 patients aged ⩽66 years enrolled on this phase II trial. 28 A 6-year follow up was later published in 2012, and showed continued superb overall results, as evidenced by the median EFS of 7.4 years. The follow-up results indicated progression in 6 out of 160 patients later than 5 years after the conclusion of treatment. 29 Finally the 15-year updated results of the Nordic MCL2 study after a median follow up of 11.4 years reported a median OS and PFS of 12.7 and 8.5 years, respectively. 30 More recent studies continue to investigate less toxic, but seemingly equally effective, induction regimens. As an example, a recent phase II study by the Dana-Farber Cancer Institute group examined a novel induction regimen consisting of three cycles of BR followed by three cycles of rituximab, high-dose cytarabine (RC) in 23 transplanteligible patients ranging from 42 to 69 years of age. The primary endpoint of this study was the CR rate after six cycles of therapy, which was met in 96% of patients. After a median follow up of 13 months, the PFS rate was 96%. These promising results warrant further investigation and validation in larger randomized controlled trials. 31 In brief, when treating a young and fit patient with MCL, an intensive strategy to maximize the length of first remission has emerged as a worldwide standard of care. With the current intensive approaches, the median PFS has surpassed 7 years. More studies are currently being conducted aiming to reduce the toxicity of intense induction regimens without compromising survival outcomes. Table 2 offers a summary.
Maintenance strategies for young and fit MCL patients
Rituximab maintenance after R-CHOP has been shown to prolong OS in elderly MCL patients treated with R-CHOP. 23 However, until just recently no data existed supporting rituximab maintenance in younger patients receiving intensive therapy. The role of rituximab maintenance following ASCT in young treatment-naïve patients was investigated in the LyMa trial. The induction regimen on this trial consisted of four cycles of R-DHAP followed by ASCT consolidation. Nonresponding patients after R-DHAP received four additional cycles of R-CHOP before ASCT. Responding patients after transplant were then assigned to either rituximab maintenance every 2 months for 3 years versus observation only. ASCT, autologous stem cell transplantation; BR, bendamustine, rituximab; CI, confidence interval; N/A, not available; NR, not reached; OS, overall survival; PFS, progression-free survival; RC, rituximab, high-dose cytarabine; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-DHAP, rituximab, dexamethasone, highdose cytarabine, cisplatin; R-HiDAC, rituximab, high-dose cytarabine; R-HyperCVAD, rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; RM-CHOP, rituximab, methotrexate, cyclophosphamide, doxorubicin, vincristine, prednisone; R-MTX/Ara-C, high-dose methotrexate/cytarabine.
and efficacy of single-agent bortezomib in relapsed or refractory MCL patients, which was shown to be associated with prolonged responses and promising survival outcomes. 33 In 2009, after a median follow up of 26.4 months, an updated report of the study indicated an mDOR of 9.2 months. The ORR was 32% (95% CI; 24-40), including 8% CR/CRu (95% CI; [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . 34 
Temsirolimus
In a phase II study, the safety and efficacy of the single-agent low-dose (25 mg weekly) mammalian target of rapamycin (mTOR) kinase inhibitor temsirolimus was examined in patients with relapsed or refractory MCL. Of 29 enrolled patients, 27 were evaluable for efficacy. The ORR was 41% (11 of 27 patients; 90% CI; 22-61%) with 1 complete response (3.7%) and 10 partial responses (37%). The median DOR for the 11 responders was 6 months (range 1-26 months). 35 In addition, Hess and colleagues conducted a multicenter, phase III study with 162 patients with R/R MCL to evaluate two dose regimens of temsirolimus in comparison with investigator's choice single-agent therapy in R/R disease. Patients were assigned to either one of the two doses of temsirolimus: 175 mg weekly for 3 weeks followed by either 
Venetoclax (ABT-199)
Venetoclax is a selective, potent, oral Bcl-2 inhibitor that has emerged as a promising agent for the treatment of patients with NHL. A phase I trial in patients with NHL was conducted to determine safety, pharmacokinetics and efficacy of venetoclax. Among 106 patients with relapsed or refractory NHL, 28 had a diagnosis of MCL and showed an ORR of 75% (21/28). The median DOR was not reported for MCL subtype. 41 Another viable option for patients with R/R MCL is reduced intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-SCT). [42] [43] [44] The decision to proceed with allo-SCT cannot be made lightly. The 2-year non-relapse mortality (NRM) rate with RIC allo-SCT is about 30% 45 and up to 50% of RIC allo-SCT patients can suffer from chronic extensive graft versus host disease (GVHD). 46 Despite these risks, the allo-SCT approach may offer the best chance for long-term survival in young R/R MCL patients, justifying the risk in selected patients. Novel agents can be utilized in an effort to gain disease control while a donor search is undertaken. new diagnosis of MCL, between 18 and 65 years of age. The primary objective of this study measures FFS. The study consists of three arms: (1) six cycles of R-CHOP alternating with R-DHAP followed by ASCT; (2) six cycles of R-CHOP alternating with R-DHAP plus ibrutinib followed by ASCT consolidation and 2 years of ibrutinib maintenance; and (3) six cycles of R-CHOP alternating with R-DHAP plus ibrutinib followed by 2 years of ibrutinib maintenance -without upfront ASCT. This study attempts to investigate whether adding ibrutinib to induction and as maintenance improves outcomes over R-CHOP/R-DHAP followed by ASCT alone. It is also designed to examine whether adding ibrutinib to induction and maintenance allows for deferral of upfront ASCT. [ClinicalTrials.gov identifier: NCT02858258]
• ECOG-ACRIN (EA4151). This is a randomized phase III trial of consolidation with ASCT followed by rituximab maintenance versus rituximab maintenance alone for patients with MCL who have achieved a negative minimal residual disease (MRD) status following induction chemotherapy. Patients, regardless of the induction regimen they have received, will be screened for MRD status. MRD-negative patients will be randomized to either ASCT + rituximab maintenance or rituximab maintenance alone without ASCT. This study aims to explore the benefit of upfront ASCT in patients who have already achieved a complete molecular remission.
Conclusion
MCL is a clinically heterogeneous disease with a highly variable clinical course, emphasizing a need for personalized approaches to optimize survival outcomes. In the past decade, multiple clinical trials factoring in the patient's age, comorbidities and tempo of the disease have resulted in significant improvement in clinical outcomes. In addition, a more detailed understanding of disease biology and pathways involved in the pathogenesis of MCL has culminated in the development of targeted agents. These agents are being integrated in clinical trials in the upfront, maintenance and R/R settings. Ongoing and future work should focus on further individualizing treatment based on tumor biology through incorporating translational studies into clinical trials to improve survival outcomes while enhancing toxicity profile associated with each treatment strategy. This goal will only be achieved by encouraging patients to participate in well-designed clinical trials to improve the understanding of disease heterogeneity, identify predictive biomarkers for response and develop more sophisticated treatment strategies.
Funding
This research received no specific grant from any funding agency in the public, commercial or notfor-profit sectors.
